

PROSTATIC CANCER - A RETROSPECTIVE STUDY OF 50 PATIENTS

IMDAD HUSSAIN¹, AZIZ MARJAN KHATTAK², S. HAMAYUN SHAH³
SALIM KHATTAK⁴ AND QAMMER JAMAL⁵

Department of Pathology, SGM Medical College, Sukkur¹
Gomal Medical College, DI Khan^{2,3}, and Ziauddin Medical University, Karachi⁵
Department of Surgery, Gomal Medical College, DI Khan⁴,

This Objective of this study was to see histologic typing of prostate cancer and its relation to patient's age, as no curative therapy exists for the advanced stages. This is a retrospective study of 50 patients suffering from prostatic adenocarcinoma and admitted at Basic Medical Sciences Institute, Jinnah Postgraduate Medical Center Karachi. A total of fifty patients between ages of 50-80 years diagnosed during the period of 1990-2001 suffering from prostate cancer were included in this study. The result showed that maximum number of tumours were in age group ranging from 61-70 years, (58% of total cases). Sixteen were (32%) well-differentiated tumours, twenty-eight (56%), moderately differentiated tumours and six (12%) were labelled as undifferentiated tumours. It was concluded that the majority of tumors were moderately differentiated tumours. Early diagnosis is useful for patients; because high grade tumours have bad prognostic markers.

Key Words: Prostate, adenocarcinoma, and histological grading.

INTRODCUTION

Adenocarcinoma of prostate is the commonest malignancy of male urinary tract and the second commonest cancer in European men¹. Many of these tumours occur in elderly people, remain latent, have a long doubling time and are of little clinical interest². However, in elderly patients, carcinoma of prostate may be an aggressive and fatal disease^{3,4}. Therefore early detection of prostate cancer is associated with an improved outcome⁵.

Factors that might predict the clinical course of the patient and the likelihood of advanced disease in early stage cancer are of great interest. Host tumour factors such as patient's age, race, hormonal factors and environment, all have a role in disease production. Clinical tumour progression, such as development of metastasis is correlated with certain microscopic features such as cell motility, nuclear features, lymphatic infiltration and blood vessel invasion.

In terms of diagnostic factors that might predict long-term outcome, include tumour grade, tumour volume and ploidy. Of these factors only tumour grade has been reliably and consistently correlated with prognosis. Tumour volume is not easily quantitated and shows low sensitivity to prognosis. DNA ploidy analysis has been shown to

correlate with prognosis but in this case sensitivity of test is also poor.

Histologic tumour grading is a strong predictor of outcome in prostate cancer. Histologic pattern strongly correlates with biological potential, a finding exploited by many grading systems proposed since the pioneering work of Broders, more than sixty years ago⁶⁻⁸. All existing grading systems successfully identify well differentiated cancers, which progress slowly, and poorly differentiated cancer, which progresses rapidly. However, the grading systems are less successful in subdividing most moderately differentiated cancers, which have an intermediate clinical and biological potential. As histological pattern of the prostate carcinoma correlates strongly with biological behavior of malignancy⁹.

It is with this back-ground that the present study was under taken to find out frequency of histologic grade in the prostate adenocarcinoma.

MATERIALS AND METHODS

This study was performed on formalin fixed paraffin embedded blocks of all cases diagnosed as adenocarcinoma of prostate glands at Department of Pathology, Basic Medical Sciences Institute, Jinnah Post Graduate Medical Center, Karachi, Pakistan. Blocks and slides of 124 cases of prostate can-

cer reported from the period 1990-2001 were retrieved. Fifty out of these were selected for histologic grading, and stained with Hematoxylin and Eosin, and read under 10X objective.

RESULTS

There were two types of specimens i.e. transurethral and suprapubic prostatectomies. The patients;

Table 1: Age Group Prostate Carcinoma

Age group		No:	%.
A	49-50	06	12
B	51-60	13	26
C	61-70	29	58
D	71-80	02	04
Total		50	100


age varied from 50-85years (mean 67.5). Table 1 shows distribution of 50 cases of prostate cancer

into different age groups. Maximum numbers of tumours among total cases were in age group ranging from 61-70 years i.e. 29 tumours (58% of total cases).


Out of Fifty cancers, sixteen (32%) were well differentiated, twenty eight (56%) were moderately differentiated and six (12%) were undifferentiated tumours as enlisted in Table 2. There is maximum number of three histologic typing in age group C of 61-70 years. The histologic findings have been shown in photomicrographs 1 to 3.

DISCUSSION


The grading system for prostate carcinoma is a strong prognostic marker. Grade is one of the strongest predictors of biological behavior in prostate cancer, including invasiveness and metastatic potential¹⁰. Every measure of recurrence and survival is strongly correlated with cancer grade, including crude survival, tumour free survival, metastasis free survival, and cause specific survival¹¹. As tumour volume increases, tumour may become progressively less differentiated. Cancer associated with an elevated serum



Photomicrography 1: Well-differentiated adenocarcinoma of prostate. H & E stain. Magnified 20X.



Photomicrograph 2: Moderately-differentiated adenocarcinoma of prostate. H & E stain. Magnified 20X.



Photomicrograph 3: Un – differentiated adenocarcinoma of prostate. H & E stain. Magnified 40X.

PSA is more likely to be of higher grade, larger volume, and more advanced pathological stage than cancer with normal PSA level^{12,13}. Grade may be related to site of origin of cancer within prostate. Cancer arising in transition zone of prostate appears to be lower grade than more common cancer arising in peripheral zone^{14,15}. Grade is included among other prognostic factors in therapeutic decision making, including patients age and health.

In present study majority of tumours were moderately differ-

entiated. The findings of the present study are in accordance with those of Ahmad and Muzaffar¹⁶.

Ziao¹⁷ found 10.5% well-differentiated tumours, 21.2% moderate differentiated tumours and 68.4% poorly differentiated tumours. Eric J¹⁸ describes well (22%), moderate (40%) and poorly (66%). The findings of previous research literature also indicates that histologic grading is a strong prognostic factor in prostate cancer. Future refinements that combines grade with other prognostic factors should allow more precise stratification of patients for treatment.

REFERENCES

1. Borre M, Nerstrom B, Overgarrrd L. The natural history of prostate carcinoma based on Danish population treated with no intent to cure. *Cancer* 1997; 80: 917-28.
2. Hirano D, Werahara PN, Crawford Ed, Lucia MS, De Antoni Ep, Miller GJ. Morphological analysis and classification of latent prostate cancer using three dimensional computer logarithms: analysis of tumour volume, grade, tumour doubling time and life expectancy. *J Urol* 1998; 159: 1256-9.
3. Dugan JA, Bostwick Dg, Myres RP. The definition and preoperative prediction of clinically insignificant prostate cancer. *JAMA* 1996; 275: 288-94.
4. Gonberg H, Damber L, Jonson K, Damber J-E. Prostate cancer mortality in northern Sweden, with special reference to tumour grade and patient age. *Urology* 1997; 49: 374-8.
5. Perotti M, Rabbani F, Farkas A, Ward S, Cummings KB. Trends in poorly differentiated prostate cancer 1973-94: observation from surveillance, epidemiology and end results database. *J Urol* 1998; 160: 811-5.
6. Broders AC. The grading carcinoma. *Minn Med* 1925; 8:726-30.
7. Gleason DF. Classification of prostate carcinoma. *Cancer Chemother Rev* 1996; 50:125-28.

Table-2: *Co-Relation of Histologic Grading with Age in Prostate Carcinoma.*

Age group	Well differentiated	Moderately differentiated	Un-differentiated
A 49 – 50	02	04	--
B 51 – 60	05	07	1
C 61 – 70	09	15	5
D 71 – 80	--	02	--
Total	16	28	6
%	32	56	12

8. Mellinger GT, Gleason D, Bailer J III. The histology and prognosis for prostate cancer, *J Urol* 1967; 97: 331-37
9. Murphy GP, Whitmore WF: A report of the workshop on the current status of the histologic grading of prostate cancer, *Cancer*, 1997; 44:1490.
10. Osterling JE, Brendler CB, Ebstein JL, Kimball Aw Jr. Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase stage in 275 patients with clinically localized adenocarcinoma of the prostate. *J Urol* 1987; 138: 92-8.
11. Brawn P, Kuhl D, Jhonson C, Pandya P, Mecord R. Stage Di prostate carcinoma. Histological appearance of nodal metastasis and its reaction to survival. *Cancer* 1990; 65:538-43.
12. Blackwell KI, Bowstwick GD, Zincke H, et al. Prostate specific antigen: its use as a practical preoperative marker of tumour burden and pathogenic stage in adenocarcinoma of prostate. *J Urol* 1994; 151: 1565-70
13. Tomita T, Dalton T, Kwok S, et al. Profile of prostatic specific antigen in prostatic adenocarcinoma. *Mod Pathol* 1993; 6: 259-64.
14. Greene DR, Wheeler Tm, Egwa S, et al. Relationship between clinical stage and histologic zone of origin in early prostate cancer. Morphometric analysis. *Br J Urol* 1991; 68: 499-507.
15. Lee F, Siders DB, Trop – Pedersen ST, et al. Prostate cancer: Transrectal ultrasound and pathology comparison. A preliminary study. Of outer gland (Peripheral and central zones) and inner gland (transition zone) cancer. *Cancer* 1991; 67: 1132-42.
16. Ahmed Z, Muzaffar S. Prostatic carcinoma with emphasis on Gleason's Grading : an institution based experience. *J Pak Med Assoc* 2002 Feb; 52 (2): 54-6.
17. Xiao LS, Niu FR, Xing et al. Clinical investigations of prostate carcinoma in the Third Teaching Hospital or Norman Bethune University of Medical Sciences. *Hinyokika Kiya*. 1998 May ; 34 (5):814-8.
18. Eric K, Kuhn, Richard A et al. Expression of the c-erbB-2 (HER-2/neu) on-coprotein in human prostatic carcinoma. *J Urol* 1999,Nov.; 150: 1427-33.